Diamyd暂停美国第3阶段试验，为其GAD65疫苗

2015年7月15日

在另一个令人失望的转弯中，Diamyd Medical于6月下旬宣布，它暂停了其GAD65疫苗二级审判。基于美国的试验检测了Diamyd在最近诊断出1型糖尿病中的β细胞功能的能力。虽然预计10月份的15个月试验将在10月完成，但对数据的初步审查表明Diamyd在保留β细胞分泌胰岛素的能力方面无效。与最近报告的欧洲第3阶段疫苗审判中缺乏疗效缺乏疗效，公司决定根据计划继续进行该研究。While these trials have casted doubt on the vaccine’s ability to slow the progression of type 1 diabetes in recently diagnosed people, Diamyd Medical believes the vaccine could still be effective in specific groups of people, when used in combination with other therapies, or in preventing type 1 diabetes. We certainly look forward to any future studies that may shed more light on these possible uses. Currently, a small prevention trial in children at high-risk of developing type 1 diabetes is being conducted in Sweden.- 布克